Question 1

Am I eligible for this trial based on my treatment history?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the A Phase I/II Study of Paclitaxel Plus Carboplatin Plus Vorinostat in Recurrent Ovarian Cancer clinical trial (NCT00772798). Contact the study team or your healthcare provider for specific answers.

Question 2

What are the potential side effects of the drugs being tested?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the A Phase I/II Study of Paclitaxel Plus Carboplatin Plus Vorinostat in Recurrent Ovarian Cancer clinical trial (NCT00772798). Contact the study team or your healthcare provider for specific answers.

Question 3

How does this treatment compare to my current options?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the A Phase I/II Study of Paclitaxel Plus Carboplatin Plus Vorinostat in Recurrent Ovarian Cancer clinical trial (NCT00772798). Contact the study team or your healthcare provider for specific answers.

Question 4

What will the treatment schedule look like, and how often will I need to visit the clinic?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the A Phase I/II Study of Paclitaxel Plus Carboplatin Plus Vorinostat in Recurrent Ovarian Cancer clinical trial (NCT00772798). Contact the study team or your healthcare provider for specific answers.

Question 5

What kind of monitoring will occur during the trial?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the A Phase I/II Study of Paclitaxel Plus Carboplatin Plus Vorinostat in Recurrent Ovarian Cancer clinical trial (NCT00772798). Contact the study team or your healthcare provider for specific answers.

Question 6

Are there any risks associated with participating in this trial?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the A Phase I/II Study of Paclitaxel Plus Carboplatin Plus Vorinostat in Recurrent Ovarian Cancer clinical trial (NCT00772798). Contact the study team or your healthcare provider for specific answers.

What this study is about